As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Kestra Medical Technologies. The largest reported stake is Bain Charger Holdings, L.P.'s, at 43.1%. 6 filings are on record since October 7, 2025 (Schedule 13G/A, February 17, 2026).
Sell to companies like Kestra Medical Technologies? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: T. Rowe Price Associates, Inc. · Sole voting: 4,966,936 · Shared voting: 0 · Sole dispositive: 4,968,900 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Holder: T. Rowe Price Associates, Inc. · Percent: 10.2% · SCHEDULE 13G/A
- · Reporting person: Bain Charger Holdings, L.P. · Sole voting: 0 · Shared voting: 25,172,338 · Sole dispositive: 0 · Shared dispositive: 25,172,338 · SCHEDULE 13G/A, 2026-02-17
- · Reporting person: Endeavour Medtech Growth II LP · Sole voting: 0 · Shared voting: 2,448,942 · Sole dispositive: 0 · Shared dispositive: 2,448,942 · SCHEDULE 13G/A, 2026-02-17
- · Holder: T. Rowe Price Associates, Inc. · Percent: 7.5% · SCHEDULE 13G
Kestra Medical Technologies has 6 Schedule 13D or 13G filings on record since 2025-10-07. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Bain Charger Holdings, L.P. | 43.1% | 25,172,338 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Fmr LLC | 10.2% | 5,225,988 | SCHEDULE 13G/A, 2025-10-07 | 2025-09-30 |
| T. Rowe Price Associates, Inc. | 8.5% | 4,968,900 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Endeavour Medtech Growth II LP | 4.2% | 2,448,942 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Kestra Medical Technologies and the warning signs.
Free to see. No signup.
Keep reading
More on Kestra Medical Technologies and the records around it.
Kestra Medical Technologies elsewhere on the record
- IPO filing Dec 2025
- Who owns it
Companies that share a holder
- Endeavour Medtech Growth II LP also filed stake reports on 1 other company: Rapid Micro Biosystems, Inc. (Feb 2026)
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: PACIFIC BIOSCIENCES OF CALIF (Nov 2026), APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Kestra Medical Technologies
Get an email when Kestra Medical Technologies files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kestra Medical Technologies?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Kestra Medical Technologies: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kestra Medical Technologies covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Bain Charger Holdings, L.P. | 0 | 25,172,338 | 0 | 25,172,338 | SCHEDULE 13G/A, 2026-02-17 |
| T. Rowe Price Associates, Inc. | 4,966,936 | 0 | 4,968,900 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Endeavour Medtech Growth II LP | 0 | 2,448,942 | 0 | 2,448,942 | SCHEDULE 13G/A, 2026-02-17 |
| Endeavour Medtech Growth II Parallel LP | 0 | 2,448,942 | 0 | 2,448,942 | SCHEDULE 13G/A, 2026-02-17 |
| Endeavour Medtech II GP Limited | 0 | 2,448,942 | 0 | 2,448,942 | SCHEDULE 13G/A, 2026-02-17 |
The latest filing identifies Kestra Medical Technologies by CUSIP G52441105 and gives its principal executive office as 3933 LAKE WASHINGTON BLVD NE, SUITE 200, KIRKLAND, WA 98033 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-07 | Fmr LLC | 10.2% | SCHEDULE 13G/A |
| 2026-02-17 | T. Rowe Price Associates, Inc. | 7.5% | SCHEDULE 13G |
| 2026-02-17 | Bain Charger Holdings, L.P. | 43.1% | SCHEDULE 13G/A |
| 2026-02-17 | Endeavour Medtech Growth II LP | 4.2% | SCHEDULE 13G/A |
| 2026-04-08 | T. Rowe Price Associates, Inc. | 10.2% | SCHEDULE 13G/A |
| 2026-08-14 | T. Rowe Price Associates, Inc. | 8.5% | SCHEDULE 13G/A |
Questions about who owns Kestra Medical Technologies
Who owns Kestra Medical Technologies?
On this page, 3 holders' latest ownership filings report 5% or more of Kestra Medical Technologies: Bain Charger Holdings, L.P. (43.1%, Schedule 13G/A, filed 2026-02-17), Fmr LLC (10.2%, Schedule 13G/A, filed 2025-10-07) and T. Rowe Price Associates, Inc. (8.5%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Kestra Medical Technologies?
By the share each holder's latest filing reports, the largest holders of Kestra Medical Technologies on this page are Bain Charger Holdings, L.P. (43.1%), Fmr LLC (10.2%) and T. Rowe Price Associates, Inc. (8.5%).
When did Bain Charger Holdings, L.P. buy into Kestra Medical Technologies?
The filings give report dates, not purchase dates. The earliest filing from Bain Charger Holdings, L.P. on this page is the Schedule 13G/A, filed 2026-02-17, reporting 43.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Kestra Medical Technologies
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 3, 2025 | IPO filing, Form 424B4 | $23 a share | IPO filings | Source |
| December 1, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| March 6, 2025 | IPO filing, Form 424B4 | $17 a share | IPO filings | Source |
| March 3, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| February 26, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| February 10, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Kestra Medical Technologies. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.